FSTX News and Press, F-star Therapeutics Inc Com

2023-04-17 17:44:40 ET Summary This month I had 5 transactions. New forward dividends are approximately $1,121. Next month I will look at Morgan Stanley, Prudential Financial, CVS Health, and Brookfield Asset Management. March was a bad month for my portfolio, as it ...

2023-03-13 00:55:00 ET Summary Sino Biopharm was approved to close its $161 million all-cash acquisition of F-star, a Cambridge, UK company that develops bispecific antibodies. Harbour BioMed announced positive results from a China Phase III trial of its anti-FcRn mAb in patients ...

2023-03-09 03:28:50 ET Summary This month, I had 5 transactions. New forward dividends are approximately $1,250. Next month, I will look into Prosus, Armada Hoffler, Enbridge, and L3harris. For further details see: My Portfolio February Update: 4 Buys...

2023-03-07 09:10:41 ET F-star Therapeutics ( NASDAQ: FSTX ) jumped 16% in premarket trading after its sale to Sino Biopharmaceuticals ( OTCPK:SBHMY ) won approval from the Committee on Foreign Investment in the U.S. CFIUS clearance is the final regulatory approv...

CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., March 07, 2023 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX) (“F-star” or the “Company”) , a clinical-stage biopharmaceutical company dedicated to developing next-generation immunotherapies to t...

2023-03-07 08:38:30 ET ThredUp ( TDUP ) +17% on Q4 earnings . Protagonist Therapeutics ( NASDAQ: PTGX ) +20% on positive topline results for Phase 2b FRONTIER 1 clinical trial of Oral IL-23 Receptor Antagonist JNJ-2113 (PN-235) in Psoriasis. BYND Cannas...

2023-03-07 08:20:14 ET F-star Therapeutics ( NASDAQ: FSTX ) jumped 15% in premarket trading on a report that its sale to Sino Biopharmaceuticals ( OTCPK:SBHMY ) is set to gain approval from the Committee on Foreign Investment in the U.S. The companies may announced t...

F-star Therapeutics ( NASDAQ: FSTX ) soared 18% after announcing that it's extended the termination date for its planned merger with invoX Pharma again as it needs additional time to "finalize" an agreement to remove CFIUS's order blocking the deal from closing. The end date is be...

Summary The recent unprecedented national security incident created by suspected Chinese spy balloons and other aerial objects ratchet up geopolitical tensions and put F-star's acquisition by Sino Biopharmaceutical at significant risk. F-star's controversial acquisition by Sino Biopharm...

F-star Therapeutics ( NASDAQ: FSTX ) rose 2.3% in premarket trading after announcing that it's extended the end date for its planned merger with invoX Pharma again as it continues to negotiate a possible mitigation agreement with CFIUS. The end date is being extended from Fri...